Premarket Approval (PMA) Summary Review Memos for 180-Day Design Changes

Description

A 180-day supplement is a request for a significant change in components, materials, design, specification, software, color additive, and labeling to an approved premarket application or premarket report. As a pilot program under the CDRH Transparency Initiative, FDA has begun releasing some summary review memos for 180-day PMA supplements relating to design changes.

Resources

Name Format Description Link
21 pmamemos.cfm http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pmamemos.cfm

Tags

  • cdrh

Topics

Categories